Table 2.

FXR agonist clinical trials.

Agonists	Clinical Trial Status	NCT Identifiers	Indication	References
Obeticholic acid	FDA approved	NCT02308111	PBC, PSC, NASH	[21]
	Phase II	NCT01585025
	Phase III	NCT02548351
EDP-305	Phase I Phase II	NCT03748628	PBC, NASH	[22]
		NCT03394924
MET409	Phase II	NCT04702490	NASH, T2DM	[27]
Cilofexor	Phase II Phase III	NCT02781584 NCT03890120	PBC, PSC, NASH	[24]
Tropifexor (LY2562175/LJN452)	Phase II	NCT02516605	PBC, NASH	[25]
Nidufexor	Phase II	NCT03804879	Diabetic Nephropathy	[26]
TERN-101(LMB-763)	Phase II	NCT04328077	NASH	[28]
EDP-297	Phase I	NCT04559126	NASH	[30]
PX-104	Phase II	NCT01999101	NAFLD	[32,33]
Vonafexor (EYP001)	Phase II Phase II	NCT03812029 NCT04365933	NASH Chronic Hepatitis B	[34]

PSC—Primary Sclerosing Cholangitis; NAFLD—non-alcoholic fatty liver disease.